Daniel Von Hoff

Dr. Von Hoff is currently Physician in Chief and Director of Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for HonorHealth’s Clinical Research Institute. He is also a Clinical Professor of Medicine, at the University of Arizona. He also holds an appointment as a Professor of Medicine at Mayo Clinic in Scottsdale, Arizona.

Dr. Von Hoff is a world-renown and recognized expert in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved at the beginning of the development of many of the agents they now use routinely, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, and others. He was a founder of ILEXTM Oncology, Inc., which was acquired by Genzyme after their products, alemtuzumab (CampathTM) and clofarabine were approved by the FDA for patients with leukemia. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.